U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's MacroglobulinemiaBusiness Wire • 09/01/21
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal CancerBusiness Wire • 08/22/21
BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström's MacroglobulinaemiaBusiness Wire • 08/18/21
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk NeuroblastomaBusiness Wire • 08/17/21
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021Business Wire • 08/16/21
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New JerseyBusiness Wire • 08/03/21
BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer PatientsBenzinga • 07/30/21
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic LeukemiaBusiness Wire • 07/30/21
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell LymphomaBenzinga • 07/26/21
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell LymphomaBusiness Wire • 07/26/21
BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma PatientsBenzinga • 07/09/21
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire • 07/09/21
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)Business Wire • 07/08/21
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid TumorsBusiness Wire • 07/07/21
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular CarcinomaBusiness Wire • 06/23/21
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström's MacroglobulinemiaBusiness Wire • 06/18/21
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung CancerBusiness Wire • 06/17/21
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To ImbruvicaBenzinga • 06/11/21